- The latest buzz surrounding Panasonic Healthcare's rumored bid for Bayer's (OTCPK:BAYRY +1%) diabetes device business pegs the price at $830M, down substantially from earlier estimates as high as $2.5B.
- Bayer intends to divest the unit in order to remain focused on its life sciences drugs. Panasonic, interested in Bayer's blood glucose meters, joins a list of Japanese electronics firms that are getting more involved in healthcare and its fatter margins.
- Previously: Bayer mulling sale of diabetes business (Nov. 24, 2014)